Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) will host a conference call and webcast on January 9, 2023, at 1:30 pm PT to present data from its Phase 1 dose-expansion trial and discuss the registrational path for STRO-002, an antibody drug conjugate targeting advanced ovarian cancer. The event will feature Dr. R. Wendel Naumann from the Levine Cancer Institute. Sutro is advancing dual ADCs in clinical studies and collaborating with major pharmaceutical companies to expand its oncology pipeline. An archived replay of the webcast will be available for 30 days.

Positive

• Sutro Biopharma is progressing STRO-002, an ADC for advanced ovarian cancer, which is in Phase 1 dose-expansion trials.
• The company has collaborations with major pharmaceutical companies, enhancing its clinical product pipeline.

Negative

• None.

- Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET -

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it will host a conference call and webcast to present data from its Phase 1 dose-expansion trial and a registrational path forward for STRO-002, an ADC being developed for the treatment of advanced ovarian cancer.

In addition to members of the Sutro management team, the call will feature Dr. R. Wendel Naumann, Investigator in the STRO-002-GM1 studies. Dr. Naumann is a professor and Director of Gynecologic Oncology Research and Associate Medical Director of Clinical Trials at the Levine Cancer Institute, Atrium Health in Charlotte, North Carolina. Dr. Naumann is also a member of Sutro's Clinical Advisory Board.

Webcast details:

• Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET
• To access and register for the live audio webcast, please go to https://ir.sutrobio.com/news-events/ir-calendar

The webcast information will also be available through the News & Events section of the Investors portion of the Company’s website at www.sutrobio.com. An archived replay will be available for at least 30 days after the event.

About Sutro Biopharma

Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma; with Merck, known as MSD outside of the United States and Canada, on MK-1484, a selective IL-2 agonist in clinical studies as a monotherapy and in combination with pembrolizumab for the treatment of solid tumors; and with Astellas Pharma (Astellas) on novel modality, immunostimulatory antibody-drug conjugates (iADCs). Sutro’s rational design and precise protein engineering has enabled six product candidates in the clinic. Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, timing of announcements of clinical results and regulatory filings, potential benefits of STRO-002 and the Company’s other product candidates and platform, potential future milestone and royalty payments, and potential market opportunities for STRO-002 and the Company’s other product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates and the Company’s ability to successfully leverage Fast Track designation, the market size for the Company’s product candidates to be smaller than anticipated, the impact of the COVID-19 pandemic on the Company’s business, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, the value of the Company’s holdings of Vaxcyte common stock, and the Company’s commercial collaborations with third parties and other risks and uncertainties described under the heading “Risk Factors” in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Investor Contact
Annie J. Chang
Sutro Biopharma
(650) 801-5728
ajchang@sutrobio.com

Media Contact
Amy Bonanno
Solebury Strategic Communications
(914) 450-0349
abonanno@soleburystrat.com

FAQ

What is Sutro Biopharma's upcoming conference call about?

Sutro Biopharma's conference call on January 9, 2023, will present data from its Phase 1 trial and discuss the registrational path for STRO-002.

When is Sutro Biopharma's conference call scheduled?

The conference call is scheduled for January 9, 2023, at 1:30 pm PT.

Who will speak at the Sutro Biopharma conference call?

Dr. R. Wendel Naumann will feature alongside Sutro's management team during the call.

What is STRO-002?

STRO-002 is an antibody drug conjugate being developed by Sutro Biopharma for the treatment of advanced ovarian cancer.

How can I access the Sutro Biopharma conference call?

You can register for the live audio webcast on Sutro's investor relations page at www.sutrobio.com.